Claims for Patent: 4,347,257

Summary for Patent: 4,347,257

Title:	Prolactin suppression in mammals
Abstract:	A method of suppressing prolactin secretion in humans by the administration of the compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof in a non-toxic, effective prolactin suppression amount (calculated as base) to a human in need thereof.
Inventor(s):	Stern; Warren C. (Raleigh, NC)
Assignee:	Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:	06/177,128
Patent Claims:	1. A method of suppressing elevated prolactin secretion in a human in which said suppression is medically desirable, which comprises administering to said human an effective non-toxic prolactin secretion suppression amount of a compound of the formula (I) ##STR3## or a pharmaceutically acceptable acid addition salt thereof. 2. The method of claim 1 in which a pharmaceutically acceptable acid addition salt thereof is administered. 3. The method of claim 2 in which the salt is the hydrochloride salt. 4. The method of claim 1 in which the human is a woman. 5. The method of claim 2 in which the human is a woman. 6. The method of claim 3 in which the human is a woman. 7. The method of claim 4 in which the compound or salt is administered in a pharmaceutically acceptable carrier therefor. 8. The method of claim 5 in which the salt is administered in a pharmaceutically acceptable carrier therefor. 9. The method of claim 6 in which the hydrochloride salt is administered in a pharmaceutically acceptable carrier therefor. 10. The method of suppressing the secretion of milk, or other fluids from the mammary gland in a human in whom suppression is desirable, which comprises administering to said human a milk secretion suppression amount of the compound m-chloro-.alpha.-t-butylaminopropiophenone or a pharmaceutically acceptable acid addition salt thereof. 11. The method of claim 10 in which the human is a woman. 12. The method of claim 10 in which the salt is the hydrochloride salt. 13. The method of claim 10 in which the compound or salt is administered in a pharmaceutically acceptable carrier therefor. 14. The method of claim 11 in which the compound or salt is administered in a pharmaceutically acceptable carrier therefor. 15. The method of claim 12 in which the salt is administered in a pharmaceutically acceptable carrier therefor. 16. The method of claim 10 in which the salt is administered, the human is a woman and the salt is administered in a pharmaceutically acceptable carrier therefor. 17. The method of reducing prolactin levels in a human suffering from prolactin sensitive mammary cancer which comprises administering to said human so suffering an effective prolactin suppression amount of m-chloro-.alpha.-t-butylaminopropiophenone or a pharmaceutically acceptable salt thereof. 18. The method of claim 1 in which a tablet or capsule containing the compound or salt is administered. 19. The method of treating a human suffering from hyperprolactenemia which comprises administering to said human so suffering an effective prolactin suppression amount of m-chloro-.alpha.-t-butylaminopropiophenone or a pharmaceutically acceptable salt thereof. 20. The method of treating a human suffering from amenorrhea resulting from hyperprolactenemia, which comprises administering to said human so suffering an effective prolactin suppression amount of m-chloro-.alpha.-t-butylaminopropiophenone or a pharmaceutically acceptable salt thereof. 21. The method of treating a human suffering from galactorrhea which comprises administering to said human so suffering an effective prolactin suppression amount of m-chloro-.alpha.-t-butylaminopropiophenone or a pharmaceutically acceptable salt thereof.